Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery

摘要: PURPOSE To analyze the outcomes of chemoradiotherapy for extrahepatic bile duct (EHBD) cancer patients who underwent R2 resection or bypass surgery and to identify prognostic factors affecting clinical outcomes, especially in terms molecular biomarkers. MATERIALS AND METHODS Medical records 21 with EHBD followed by from May 2001 June 2010 were retrospectively reviewed. All surgical specimens re-evaluated immunohistochemical staining using phosphorylated protein kinase B (pAKT), CD24, matrix metalloproteinase 9 (MMP9), survivin, β-catenin antibodies. The relationship between results was investigated. RESULTS At a median follow-up 20 months, actuarial 2-year locoregional progression-free, distant metastasis-free overall survival 37%, 56%, 54%, respectively. On univariate analysis clinicopathologic factors, there no significant factor. In staining, cytoplasmic nuclear pAKT positive 10 6 patients, There CD24 7 MMP9 16 survivin 8 3 patients. analysis, value outcomes. CONCLUSION association received after pAKT, MMP9, β-catenin. Future research is needed on larger data set other